COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL

The aim of the review article was to highlight the methodologies for assessing the financial costs of adverse drug reactions exemplified by the Russian Federation and Brazil.Materials and methods: for a comparative analysis, materials from open sources were used. The study of the experience of metho...

Full description

Saved in:
Bibliographic Details
Main Authors: G. I. Syraeva, A. S. Kolbin, A. V. Matveev, V. S. Panezhina
Format: Article
Language:Russian
Published: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2021-03-01
Series:Фармация и фармакология (Пятигорск)
Subjects:
Online Access:https://www.pharmpharm.ru/jour/article/view/740
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839574309753847808
author G. I. Syraeva
A. S. Kolbin
A. V. Matveev
V. S. Panezhina
author_facet G. I. Syraeva
A. S. Kolbin
A. V. Matveev
V. S. Panezhina
author_sort G. I. Syraeva
collection DOAJ
description The aim of the review article was to highlight the methodologies for assessing the financial costs of adverse drug reactions exemplified by the Russian Federation and Brazil.Materials and methods: for a comparative analysis, materials from open sources were used. The study of the experience of methods used for assessing the burden of adverse drug reactions, was carried out using the system for calculating payments for medical care by clinical-statistical and clinical-profile groups, the methodology for assessing the severity of adverse events of the US National Cancer Institute, drug-associated problems, and “the decision tree” model.Results. When comparing the costs of ADR management in the Russian Federation and Brazil, the following results have been obtained: in the Russian Federation, the “cost” of reaction can be estimated only for a limited number of nosological groups that are regulated by the classification of diseases by clinical and statistical groups; in Brazil, when predicting the costs of adverse reactions management, the combination of “the decision tree” method and the Delphi method is used. In the Russian Federation, the cost of the 3rd and above severity adverse event (according to CTCAE v. 4.03), varies from 26,849.22 up to 26,196.37 RUB in the North-West region (St. Petersburg). In Brazil, the cost of ADR ranges from 13 USD (the best scenario for the patient) to 574 USD (the worst scenario for the patient), which is about 975 and 43,000 RUB, respectively. The introduction of methods that make it possible to predict the development and potential outcomes of adverse drug reactions, as well as taking into account the experiences of foreign colleagues in their modeling, will reduce economic costs in the Russian Federation at the federal level.Conclusion: for the economic value analysis and further forecasting, an improvement of existing methodologies is required. The models used in the Russian Federation (“the decision tree”, classification of diseases by clinical groups, Markov model) do not take into account the time factor, therefore, when planning the analysis of potential costs for adverse reactions, it is necessary to reinforce the methods with such tools as QALY, YLL, and YLD.
format Article
id doaj-art-220b2bc2b8224370a873ab0fac3f1d0f
institution Matheson Library
issn 2307-9266
2413-2241
language Russian
publishDate 2021-03-01
publisher Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
record_format Article
series Фармация и фармакология (Пятигорск)
spelling doaj-art-220b2bc2b8224370a873ab0fac3f1d0f2025-08-04T13:58:40ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412021-03-018533634410.19163/2307-9266-2020-8-5-336-344356COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZILG. I. Syraeva0A. S. Kolbin1A. V. Matveev2V. S. Panezhina3First St. Petersburg State Medical University named after academician I.P. Pavlov; Research Center ”Eco-safety”First St. Petersburg State Medical University named after academician I.P. Pavlov“Crimean Federal University named after S.I. Vernadsky”; Russian Medical Academy of Continuing Professional Education (RMA CPE)Research Center ”Eco-safety”The aim of the review article was to highlight the methodologies for assessing the financial costs of adverse drug reactions exemplified by the Russian Federation and Brazil.Materials and methods: for a comparative analysis, materials from open sources were used. The study of the experience of methods used for assessing the burden of adverse drug reactions, was carried out using the system for calculating payments for medical care by clinical-statistical and clinical-profile groups, the methodology for assessing the severity of adverse events of the US National Cancer Institute, drug-associated problems, and “the decision tree” model.Results. When comparing the costs of ADR management in the Russian Federation and Brazil, the following results have been obtained: in the Russian Federation, the “cost” of reaction can be estimated only for a limited number of nosological groups that are regulated by the classification of diseases by clinical and statistical groups; in Brazil, when predicting the costs of adverse reactions management, the combination of “the decision tree” method and the Delphi method is used. In the Russian Federation, the cost of the 3rd and above severity adverse event (according to CTCAE v. 4.03), varies from 26,849.22 up to 26,196.37 RUB in the North-West region (St. Petersburg). In Brazil, the cost of ADR ranges from 13 USD (the best scenario for the patient) to 574 USD (the worst scenario for the patient), which is about 975 and 43,000 RUB, respectively. The introduction of methods that make it possible to predict the development and potential outcomes of adverse drug reactions, as well as taking into account the experiences of foreign colleagues in their modeling, will reduce economic costs in the Russian Federation at the federal level.Conclusion: for the economic value analysis and further forecasting, an improvement of existing methodologies is required. The models used in the Russian Federation (“the decision tree”, classification of diseases by clinical groups, Markov model) do not take into account the time factor, therefore, when planning the analysis of potential costs for adverse reactions, it is necessary to reinforce the methods with such tools as QALY, YLL, and YLD.https://www.pharmpharm.ru/jour/article/view/740adverse drug reactionspharmacovigilancepharmacoeconomicsmodelingdisease burden
spellingShingle G. I. Syraeva
A. S. Kolbin
A. V. Matveev
V. S. Panezhina
COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
Фармация и фармакология (Пятигорск)
adverse drug reactions
pharmacovigilance
pharmacoeconomics
modeling
disease burden
title COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
title_full COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
title_fullStr COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
title_full_unstemmed COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
title_short COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL
title_sort comparative review of methodologies for estimating the cost of adverse drug reactions in the russian federation and brazil
topic adverse drug reactions
pharmacovigilance
pharmacoeconomics
modeling
disease burden
url https://www.pharmpharm.ru/jour/article/view/740
work_keys_str_mv AT gisyraeva comparativereviewofmethodologiesforestimatingthecostofadversedrugreactionsintherussianfederationandbrazil
AT askolbin comparativereviewofmethodologiesforestimatingthecostofadversedrugreactionsintherussianfederationandbrazil
AT avmatveev comparativereviewofmethodologiesforestimatingthecostofadversedrugreactionsintherussianfederationandbrazil
AT vspanezhina comparativereviewofmethodologiesforestimatingthecostofadversedrugreactionsintherussianfederationandbrazil